tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

AVIR Stock Latest News

Atea Pharmaceuticals announces first patient dosed in Phase 3 C-FORWARD trial
The FlyAtea Pharmaceuticals announces first patient dosed in Phase 3 C-FORWARD trial
5d ago
AVIR
Atea Pharmaceuticals Holds 2025 Annual Stockholders Meeting
PremiumCompany Announcements
Atea Pharmaceuticals Holds 2025 Annual Stockholders Meeting
9d ago
8K
AVIR
Atea Pharmaceuticals Advances HCV Treatment Trials
PremiumCompany Announcements
Atea Pharmaceuticals Advances HCV Treatment Trials
2M ago
AVIR
AVIR Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
AVIR Upcoming Earnings Report: What to Expect?
2M ago
AVIR
Atea announces results of Phase 2 study of bemnifosbuvir, ruzasvir
PremiumThe Fly
Atea announces results of Phase 2 study of bemnifosbuvir, ruzasvir
2M ago
AVIR
Atea Pharmaceuticals to host hepatitis C virus KOL panel
PremiumThe FlyAtea Pharmaceuticals to host hepatitis C virus KOL panel
2M ago
AVIR
Atea Pharmaceuticals announces results from phase 2 study of bemnifosbuvir
Premium
The Fly
Atea Pharmaceuticals announces results from phase 2 study of bemnifosbuvir
2M ago
AVIR
Atea Pharmaceuticals Announces Board Changes and Share Buyback
Premium
Company Announcements
Atea Pharmaceuticals Announces Board Changes and Share Buyback
2M ago
8K
AVIR
Atea Pharmaceuticals board authorizes $25M share repurchase program
PremiumThe Fly
Atea Pharmaceuticals board authorizes $25M share repurchase program
2M ago
AVIR
Atea Pharmaceuticals says strategic alternatives process ‘ongoing’
PremiumThe Fly
Atea Pharmaceuticals says strategic alternatives process ‘ongoing’
2M ago
AVIR
Atea Pharmaceuticals appoints Howard Berman to board of directors
PremiumThe Fly
Atea Pharmaceuticals appoints Howard Berman to board of directors
2M ago
AVIR
COYA
Atea Pharmaceuticals price target lowered to $6 from $6.20 at Morgan Stanley
PremiumThe Fly
Atea Pharmaceuticals price target lowered to $6 from $6.20 at Morgan Stanley
3M ago
AVIR
Atea Pharmaceuticals doses first patient in C-BEYOND, Phase 3 study
PremiumThe FlyAtea Pharmaceuticals doses first patient in C-BEYOND, Phase 3 study
3M ago
AVIR
Atea Pharmaceuticals cuts 25% of workforce, exploring partnerships
Premium
The Fly
Atea Pharmaceuticals cuts 25% of workforce, exploring partnerships
3M ago
AVIR
Radoff-JEC Group nominates candidates to Atea Pharmaceuticals board
Premium
The Fly
Radoff-JEC Group nominates candidates to Atea Pharmaceuticals board
3M ago
AVIR
Atea Pharmaceuticals issues statement regarding director nominations
PremiumThe Fly
Atea Pharmaceuticals issues statement regarding director nominations
3M ago
AVIR
Atea Pharmaceuticals announces presentation of bemnifosbuvir preclinical data
PremiumThe Fly
Atea Pharmaceuticals announces presentation of bemnifosbuvir preclinical data
3M ago
AVIR
Atea Pharmaceuticals Faces Challenges Amid Workforce Reductions and Cost-Cutting Efforts
PremiumCompany Announcements
Atea Pharmaceuticals Faces Challenges Amid Workforce Reductions and Cost-Cutting Efforts
4M ago
AVIR
Atea Pharmaceuticals’ Promising Earnings Call Highlights
PremiumCompany Announcements
Atea Pharmaceuticals’ Promising Earnings Call Highlights
4M ago
AVIR
Atea Pharmaceuticals Advances HCV Program with FDA Approval
PremiumCompany AnnouncementsAtea Pharmaceuticals Advances HCV Program with FDA Approval
4M ago
AVIR
Atea Pharmaceuticals reports Q4 EPS (40c), consensus (29c)
Premium
The Fly
Atea Pharmaceuticals reports Q4 EPS (40c), consensus (29c)
4M ago
AVIR
AVIR Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
AVIR Upcoming Earnings Report: What to Expect?
4M ago
AVIR

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >